The global BPH treatment market is expected to grow from USD 33,031.10 million in 2024 to USD 47,045.80 million by 2034, at a ...

Defense Secretary Lloyd Austin was hospitalized in 2024 and given medication that could affect his cognitive functions before he transferred his authority.

The FDA has approved Gemtesa® for men with overactive bladder symptoms receiving pharmacological therapy for BPH.